|
| About Dr. Reddy’s |
Dr. Reddy's Laboratories is a global, vertically integrated company with a presence across the pharmaceutical value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biotechnology products, which are marketed to over 100 countries including US, Europe, Russia, Asia Pacific, India and China.
The Company conducts NCE drug discovery research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. Its drug discovery effort is carried out at its research facilities in Atlanta, USA, and in Hyderabad, India.
|
| |
|
| Company Locations |
| Corporate headquarters: |
| Hyderabad, India |
| Research Facilities in: |
| Atlanta, USA &
Hyderabad, India |
| Manufacturing Facilities in: |
6 Facilities of Active Pharmaceutical ingredients in AP, India
2 Technology Development Centres for Custom Pharmaceutical Services (CPS) in India and I facility of CPS in Cuvernavaca, Mexico.
6 Finished Dosage Units in India.
1 Biologics facility in India |
| Worldwide offices: |
| Albania, Baltic, Belarus, Brazil, Bulgaria, Cambodia, China, Dominican Republic, Ecuador, Fiji, Germany, Ghana, Haiti, India, Iraq, Jamaica, Kazakhstan, Kenya, Kosovo, KSA, KLCG, Kuwait, Macedonia, Malaysia, Mexico, Moldova, Myanmar, New Zealand, Nigeria, Oman, Peru, Philippines, Romania, Russia, Serbia, Singapore, South Africa, Spain, Sri Lanka, Sudan, Switzerland, Tanzania, Thailand, Trinidad, UAE, Uganda, Ukraine, United Kingdom, United States of America, Uzbekistan, Venezuela, Vietnam. |
| People: |
|
Employees: over 8500 |
|
Sales Staff: over 1,700 worldwide |
|
Scientists: more than 850 of whom over 200 are dedicated to drug discovery |
|
| Financials: |
|
Net Revenues for fiscal year 2006 at US $546 million |
|
Net income for fiscal year 2006 at $37 million. |
|
| Businesses: |
|
Discovery Research |
|
Six New Chemical Entities in the Discovery Pipeline. Two in clinical development and four in pre-clinical development. |
|
Active Pharmaceutical Ingredients |
|
Over 100 molecules (API) developed and sixty of them are being marketed worldwide. |
|
Branded Formulations |
|
Manufacturing and marketing branded formulations globally, including India, Russia, China and Brazil. |
|
Generic Formulations |
|
Manufacturing and Marketing generic formulations to regulated markets which include the US, UK, South Africa and Australia. |
|
Specialty Formulations |
|
Focused on the US market. Currently one product application is pending approval with the US Food and Drug Administration. Several more in the pipeline. Focused on the prescription dermatology segment. |
|
Biogenerics |
|
Developed filgrastim (generic name) from molecular biology stage to commericialisation. Several more biogenerics in development. |
|
Custom Pharmaceutical Services |
|
A complete range of process development and manufacturing services. A dedicated process research and development facility. |
|
|
|
|
| Triple Bottom Line |
 |
|
|
| Download Brochures |
 |
|
|
| Key Milestones |
 |
|
|
|
|
